Martina M.D. Flammer Sells 9,925 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 9,925 shares of the business’s stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $65.47, for a total transaction of $649,789.75. Following the transaction, the insider now owns 86,596 shares in the company, valued at $5,669,440.12. This represents a 10.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, May 16th, Martina M.D. Flammer sold 1,799 shares of Insmed stock. The stock was sold at an average price of $67.53, for a total transaction of $121,486.47.
• On Wednesday, May 14th, Martina M.D. Flammer sold 1,744 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $114,423.84.
• On Tuesday, May 13th, Martina M.D. Flammer sold 8,408 shares of Insmed stock. The stock was sold at an average price of $67.81, for a total transaction of $570,146.48.

Insmed Stock Up 0.9%

Shares of NASDAQ INSM opened at $68.51 on Wednesday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market capitalization of $12.48 billion, a P/E ratio of -12.26 and a beta of 0.84. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The company has a 50-day moving average price of $71.32 and a 200-day moving average price of $73.13.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. During the same period in the prior year, the firm posted ($1.06) EPS. The business’s revenue was up 22.9% on a year-over-year basis. On average, equities research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on INSM shares. Guggenheim reiterated a “buy” rating and issued a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. UBS Group dropped their price objective on shares of Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat, Insmed currently has an average rating of “Moderate Buy” and an average target price of $94.63.

Institutional Trading of Insmed

Several hedge funds and other institutional investors have recently modified their holdings of the business. Cullen Frost Bankers Inc. grew its stake in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 221 shares in the last quarter. Elequin Capital LP purchased a new position in Insmed during the fourth quarter valued at approximately $28,000. Steward Partners Investment Advisory LLC grew its stake in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC grew its stake in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares in the last quarter. Finally, Spire Wealth Management purchased a new position in Insmed during the fourth quarter valued at approximately $47,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.